This highly potent combination of CoQ10 and omega-3 EPA/DHA fatty acids provides cardiovascular and cognitive benefits through multiple distinct and overlapping pathways. CoQ10 and EPA/DHA have been shown to improve endothelial function, particularly in populations at risk for atherosclerosis (high BMI, metabolic syndrome, smoking, hyperlipidemia), with clinically significant hypotensive and anti-atherogenic effects.
CoQ10 plays a critical role in oxidative phosphorylation and mitochondrial bioenergetics, essential for neuronal health and the prevention of mitochondrial dysfunction that underlies many chronic diseases, including neurodegenerative diseases. Furthermore, recent data highlight the emerging role of CoQ10 in reducing inflammation and insulin resistance, which are major contributors to impaired cognitive function. A meta-analysis of randomized trials showed that CoQ10 and EPA/DHA supplementation reduced key biomarkers of inflammation, including C-reactive protein, TNF-alpha, and IL-6. Serum CoQ10 levels have also been associated with neurological outcomes after ischemic stroke, as well as the risk of disabling dementia.
OptiMega-3 Q10 also provides high doses of pharmaceutical-grade EPA/DHA, which has been shown to reduce many cardiovascular risk factors and improve vascular function, with controlled clinical trials demonstrating a reduced rate of cardiovascular and coronary events, particularly in high-risk individuals. Omega-3 fatty acids have been associated with a reduction in myocardial infarction and stroke, with supplementation mitigating negative left ventricular changes, myocardial fibrosis, and systemic inflammation following myocardial infarction. EPA/DHA supports cognitive function through multiple mechanisms, as they are both essential for neuronal membranes, with lower levels being not only a marker of neurological disease but also a risk factor for cognitive impairment.